HC Wainwright Boosts Altimmune (NASDAQ:ALT) Price Target to $25.00

Altimmune (NASDAQ:ALT) had its price target boosted by research analysts at HC Wainwright from $12.00 to $25.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

ALT has been the subject of a number of other research reports. Wall Street Zen downgraded shares of Altimmune from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a research report on Monday, December 29th. William Blair restated a “market perform” rating on shares of Altimmune in a research report on Thursday, March 5th. Barclays started coverage on Altimmune in a report on Tuesday, January 27th. They issued an “overweight” rating and a $20.00 target price for the company. Finally, B. Riley Financial cut their price target on Altimmune from $18.00 to $13.00 and set a “buy” rating on the stock in a report on Friday, March 6th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Altimmune has a consensus rating of “Hold” and an average target price of $19.20.

Altimmune Trading Up 3.9%

ALT stock traded up $0.14 during trading on Monday, hitting $3.64. The company had a trading volume of 868,177 shares, compared to its average volume of 4,656,449. The stock has a market cap of $472.80 million, a PE ratio of -3.58 and a beta of 0.13. The business has a 50-day moving average of $4.50 and a 200-day moving average of $4.30. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.15. Altimmune has a one year low of $2.90 and a one year high of $7.73.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Thursday, March 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). Altimmune had a negative return on equity of 49.35% and a negative net margin of 214,860.98%.The firm had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.00 million. Research analysts predict that Altimmune will post -1.35 earnings per share for the current fiscal year.

Insider Transactions at Altimmune

In other news, CEO Jerome Benedict Durso purchased 20,000 shares of the business’s stock in a transaction on Friday, March 6th. The shares were acquired at an average price of $3.54 per share, for a total transaction of $70,800.00. Following the completion of the acquisition, the chief executive officer owned 32,500 shares in the company, valued at approximately $115,050. The trade was a 160.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director John Gill acquired 12,500 shares of the firm’s stock in a transaction dated Tuesday, December 23rd. The shares were purchased at an average price of $4.10 per share, with a total value of $51,250.00. Following the acquisition, the director owned 12,500 shares of the company’s stock, valued at approximately $51,250. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 55,527 shares of company stock worth $213,778 in the last three months. Insiders own 4.40% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Arax Advisory Partners grew its holdings in shares of Altimmune by 99.7% during the fourth quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock valued at $29,000 after buying an additional 4,076 shares during the last quarter. SBI Securities Co. Ltd. increased its position in shares of Altimmune by 27.9% during the fourth quarter. SBI Securities Co. Ltd. now owns 8,837 shares of the company’s stock worth $32,000 after acquiring an additional 1,928 shares in the last quarter. Quadrature Capital Ltd acquired a new stake in shares of Altimmune in the 4th quarter worth about $36,000. Victory Capital Management Inc. acquired a new stake in shares of Altimmune in the 3rd quarter worth about $38,000. Finally, CreativeOne Wealth LLC bought a new position in Altimmune in the 4th quarter valued at about $38,000. 78.05% of the stock is owned by institutional investors.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.